Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

December 11, 2023

https://www.globenewswire.com/news-release/2023/12/11/2793874/0/en/Mustang-Bio-Presents-Updated-Phase-1-2-Multicenter-Clinical-Data-for-MB-106-at-the-2023-American-Society-of-Hematology-ASH-Annual-Meeting.html

   Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma

Read more at globenewswire.com

Related news for (MBIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.